We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Heart Attack Test Better Informs Underlying Condition

By LabMedica International staff writers
Posted on 27 Mar 2018
The serum troponin assay is the biochemical gold standard for detecting myocardial infarction (MI). More...
A major diagnostic issue is that some believe troponin levels can rise with reversible injury, in the absence of radiologically detectable infarct.

Cardiac troponin is a protein unique to the heart, so elevated levels in the blood indicate that the heart has been damaged. The cardiac troponin blood test is still the current gold standard test used for the clinical diagnosis of MI or death of heart muscle due to lack of blood supply, but the test does not indicate the extent of cardiac damage.

Medical scientists at the University of Alberta Faculty of Medicine & Dentistry (Edmonton, AB, Canada) hypothesized that because cell death activates intracellular proteases, troponin released by irreversible infarct will be more proteolyzed than that released by milder processes. Their goal was to quantify proteolytic digestion of cardiac troponin I in patients with varying degrees of myocardial injury.

The team analyzed serum or plasma samples from 29 patients with cardiac troponin I elevations for proteolytic degradation, using three different sandwich enzyme-linked immunosorbent assays (ELISAs) designed to specifically detect the N-terminal, core, or C-terminal regions of cardiac troponin I. As predicted, the degree of proteolytic digestion increased with increasing severity of injury, as estimated by the total troponin level, and this trend was more pronounced for C-terminal versus N-terminal degradation. The highest degree of proteolytic digestion was observed in patients with ST-elevation MI; the least, in type 2 MI which is supply–demand ischemia rather than acute thrombus formation.

The authors concluded that the proteolytic degradation pattern of cardiac troponin I may be a better indicator of clinically significant MI than total serum troponin level. Distinguishing between intact and degraded forms of troponin may be useful for (a) identifying those patients with clinically significant infarct in need of revascularization, (b) monitoring intracellular proteolysis as a possible target for therapeutic intervention, and (c) providing an impetus for standardizing the epitopes used in the troponin I assay.

Peter M. Hwang, MD, an assistant professor and lead investigator of the study, said, “We postulated that when cells die during a heart attack, not only would they release troponin into the bloodstream, but they would also digest the troponin through the action of activated intracellular proteases, enzymes that digest other proteins. As predicted, we found that the degree of proteolytic digestion increased with increasing severity of heart injury.” The study was published in the February 2018 issue of the Journal of Applied Laboratory Medicine.

Related Links:
University of Alberta Faculty of Medicine & Dentistry


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.